Inflammatory cell influx

"Inflammatory cell influx" refers to the process—not a specific molecule or receptor—by which immune cells such as neutrophils, monocytes/macrophages, lymphocytes, and others are recruited from the bloodstream into tissues at sites of injury or infection. This process is orchestrated by a complex network involving endothelial activation; upregulation of adhesion molecules like selectins and integrins; secretion of chemotactic factors including chemokines; increased vascular permeability; and subsequent transmigration across the endothelium via diapedesis. The initial phase typically involves rapid neutrophil recruitment followed by monocyte/macrophage infiltration. These events are essential for pathogen clearance but must be tightly regulated to prevent excessive tissue damage. Dysregulation can lead to chronic inflammation or impaired resolution seen in various diseases including cardiovascular disorders, autoimmune conditions, infections, and chronic wounds[1][3][4][6][7]. Drugs targeting this process act mainly by interfering with mediators that drive cellular recruitment rather than directly binding a single molecular target. Note: "Inflammatory cell influx" is not itself a discrete molecular entity but describes an important biological phenomenon involving many targets. It should not be considered a canonical therapeutic target like an enzyme or receptor but rather an outcome/process resulting from multiple molecular interactions[1][3][4].

Other names

Inflammatory cell recruitmentLeukocyte influxImmune cell infiltrationCellular infiltration in inflammation

Inhibition of pro-inflammatory mediator synthesis (e.g., NSAIDs inhibit cyclooxygenase enzymes to reduce prostaglandin-mediated vasodilation and permeability); Suppression of cytokine/chemokine signaling pathways that attract immune cells to sites of inflammation; Blockade of adhesion molecules or chemokine receptors involved in leukocyte migration.